Tags : (olaratumab)

Eli Lilly Facilitates the Withdrawal of Lartruvo (olaratumab) from the

Shots: The withdrawal follows the failure of P-III ANNOUNCE study assessing Lartruvo (olaratumab) + doxorubicin followed by Lartruvo as monothx vs doxorubicin + PBO followed by PBO in patients with advanced or metastatic STS, resulted with no improvement in survival of patients Lilly to establish a program ensuring current patients access to Lartruvo with limited […]Read More

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Shots: The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS The study didn’t meet 1EP as OS showing no difference in survival rate with no safety signals observed; AEs (all grades; grade 3-4) fatigue (69%,9% vs 3% […]Read More